Adolfo de la Fuente

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

Julio García‐Suárez, Javier de la Cruz, Ángel Cedillo et al. · Journal of Hematology & Oncology · 2020 · 238 citations · Full text

Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)

Francisco‐Javier Peñalver, Juan‐Manuel Sancho, Adolfo de la Fuente et al. · Haematologica · 2016 · 64 citations · Full text

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Eva Giné, Fátima De la Cruz, Ana Jiménez Ubieto et al. · Journal of Clinical Oncology · 2022 · 57 citations · Full text

Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine

Teresa Bennett, Pau Montesinos, Federico Moscardó et al. · Clinical Lymphoma Myeloma & Leukemia · 2013 · 34 citations · Full text

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Naval Daver, Pau Montesinos, Ahmed Aribi et al. · Blood · 2022 · 25 citations